Clinical Trial: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Neoplasms
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Nirapari
Brief Summary:
The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc).The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Read more